ArticleScientific reports2026
A lasso-based model combining miRNA and clinical variables predicts future risk of breast and ovarian cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Hereditary breast and ovarian cancer syndrome (HBOC) is principally caused by germline mutations in BRCA1 and BRCA2. However, most women with HBOC are undiagnosed, and some patients meeting clinical criteria for HBOC will have no identifiable mutation after genetic testing. Here, we deploy a lasso-based model to combine serum miRNA profiles with clinical data to identify women at elevated risk for ovarian cancer among a population of 1831 individuals enrolled in an institutional biobank. The miRNA and metadata variables are mapped to two-dimensional space using lasso, after which a linear classification model is trained to estimate "BRCAness" and long-term risk of cancer. After tenfold cross-validation, the method offers a BRCA prediction AUC score of 0.98 (95% CI 0.94-1.0) and generalizes across subgroups stratified by age, cancer history, and racial/ethnic group. To demonstrate the clinical relevance of this phenotype, we use the lasso-based model to assess 5-year ovarian cancer risk among an independent cohort of 1044 subjects agnostic to genetic testing results enrolled in a randomized clinical trial. In this unselected population, the output of the lasso-based model strongly correlates to the log 5-year relative risk of ovarian cancer (R = 0.93, 95% CI 0.83-0.97, p < 0.0001). When the model was used to predict future onset of ovarian cancer directly, the AUC offered was AUC = 0.75 (95% CI 0.70-0.78). Together, these data suggest the proposed model is a predictor of future ovarian cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.